Full text · 原文
Body text not extracted for this record.
View on the original government site →
View on the original government site →
Record · 深圳市发展和改革委员会
ACC. 12276811
2025 National Reimbursement Drug List Adjustment Launched, Greater Support for 'Genuine Innovation'
2025年医保目录调整启动 支持“真创新”力度更大
Issuer
深圳市发展和改革委员会
Date
2025-07-14 10:00:02
Instrument
other
Cited by
0
This document announces the launch of the 2025 adjustment process for China's National Reimbursement Drug List (NRDL), emphasizing a strengthened focus on including and supporting genuinely innovative pharmaceuticals.